InsiderTrades

Form 4 for RCKT ROCKET PHARMACEUTICALS, INC.

Accepted 2025-10-08 00:00:00 ET · period of report 2025-10-06 · accession 0001140361-25-037683 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-10-08 2025-10-06 RCKT Rizvi Syed Ali-aamir Chief Medical Off A - Grant $0.00 +345.9K 283.0K New $0
D 2025-10-08 2025-10-06 RCKT Rizvi Syed Ali-aamir Chief Medical Off A - Grant $0.00 +383.9K 383.9K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-10-06 A A 62,893 $0.00 345,911 D — — (F2) Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries.
2 Common Common Stock 2025-10-06 A A 283,018 $0.00 283,018 D — — (F1) Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
3 Derivative Stock Option (right to buy) 2025-10-06 A A 383,854 $0.00 383,854 D $3.18 · 2028-10-06 to 2035-10-06 383,854 Common Stock (F3) Represents non-qualified stock options ("NQSOs") that convert to common stock on a one-for-one basis. One-third (1/3) of such NQSOs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.